Literature DB >> 23838920

Age as a prognostic factor in patients with localized melanoma and regional metastases.

Charles M Balch1, Seng-jaw Soong, Jeffrey E Gershenwald, John F Thompson, Daniel G Coit, Michael B Atkins, Shouluan Ding, Alistair J Cochran, Alexander M M Eggermont, Keith T Flaherty, Phyllis A Gimotty, Timothy M Johnson, John M Kirkwood, Stanley P Leong, Kelly M McMasters, Martin C Mihm, Donald L Morton, Merrick I Ross, Vernon K Sondak.   

Abstract

BACKGROUND: We postulated that the worse prognosis of melanoma with advancing age reflected more aggressive tumor biology and that in younger patients the prognosis would be more favorable.
MATERIALS AND METHODS: The expanded AJCC melanoma staging database contained 11,088 patients with complete data for analysis, including mitotic rate.
RESULTS: With increasing age by decade, primary melanomas were thicker, exhibited higher mitotic rates, and were more likely to be ulcerated. In a multivariate analysis of patients with localized melanoma, thickness and ulceration were highly significant predictors of outcome at all decades of life (except for patients younger than 20 years). Mitotic rate was significantly predictive in all age groups except patients <20 and >80 years. For patients with stage III melanoma, there were four independent variables associated with patient survival: number of nodal metastases, patient age, ulceration, and mitotic rate. Patients younger than 20 years of age had primary tumors with slightly more aggressive features, a higher incidence of sentinel lymph node metastasis, but, paradoxically, more favorable survival than all other age groups. In contrast, patients >70 years old had primary melanomas with the most aggressive prognostic features, were more likely to be head and neck primaries, and were associated with a higher mortality rate than the other age groups. Surprisingly, however, these patients had a lower rate of sentinel lymph node metastasis per T stage. Among patients between the two age extremes, clinicopathologic features and survival tended to be more homogeneous.
CONCLUSIONS: Melanomas in patients at the extremes of age have a distinct natural history.

Entities:  

Mesh:

Year:  2013        PMID: 23838920      PMCID: PMC4121330          DOI: 10.1245/s10434-013-3100-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  39 in total

1.  Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.

Authors:  John F Thompson; Seng-Jaw Soong; Charles M Balch; Jeffrey E Gershenwald; Shouluan Ding; Daniel G Coit; Keith T Flaherty; Phyllis A Gimotty; Timothy Johnson; Marcella M Johnson; Stanley P Leong; Merrick I Ross; David R Byrd; Natale Cascinelli; Alistair J Cochran; Alexander M Eggermont; Kelly M McMasters; Martin C Mihm; Donald L Morton; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Melanoma survival in the United States, 1992 to 2005.

Authors:  Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack
Journal:  J Am Acad Dermatol       Date:  2011-11       Impact factor: 11.527

3.  Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients.

Authors:  Sabela Paradela; Eduardo Fonseca; Salvador Pita-Fernández; Sara M Kantrow; Abdul H Diwan; Cynthia Herzog; Victor G Prieto
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

4.  Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model.

Authors:  Martin Wiener; Katharine M Acland; Helen M Shaw; Seng-Jaw Soong; Hui-Yi Lin; Dung-Tsa Chen; Richard A Scolyer; Julie B Winstanley; John F Thompson
Journal:  Ann Surg Oncol       Date:  2010-05-20       Impact factor: 5.344

5.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.

Authors:  John J Strouse; Thomas R Fears; Margaret A Tucker; Alan S Wayne
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

6.  Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status.

Authors:  Cristina R Ferrone; Katherine S Panageas; Klaus Busam; Mary Sue Brady; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

Review 7.  Cutaneous melanoma in the elderly.

Authors:  Alessandro Testori; Javier Soteldo; Daniele Sances; Giovanni Mazzarol; Giuseppe Trifirò; Mark Zonta; Marco Rastrelli; Francesco Schenone; Francesco Verrecchia
Journal:  Melanoma Res       Date:  2009-06       Impact factor: 3.599

8.  Trends in pediatric melanoma mortality in the United States, 1968 through 2004.

Authors:  Kevan G Lewis
Journal:  Dermatol Surg       Date:  2007-12-17       Impact factor: 3.398

9.  Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

Authors:  Maria Daniotti; Andrea Ferrari; Simona Frigerio; Paola Casieri; Francesca Miselli; Elisa Zucca; Paola Collini; Gabriella Della Torre; Siranoush Manoukian; Bernard Peissel; Aldo Bono; Mario Santinami; Giorgio Parmiani; Licia Rivoltini; Silvana Pilotti; Monica Rodolfo
Journal:  J Invest Dermatol       Date:  2009-01-22       Impact factor: 8.551

10.  The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center.

Authors:  Sander Sassen; Helen M Shaw; Marjorie H Colman; Richard A Scolyer; John F Thompson
Journal:  Ann Surg Oncol       Date:  2007-12-14       Impact factor: 5.344

View more
  44 in total

1.  Something Old, Something New: The Tumor Microenvironment Comes of Age.

Authors:  Kerrie L Marie; Glenn Merlino
Journal:  Cancer Discov       Date:  2019-01       Impact factor: 39.397

2.  Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Authors:  Alexander H R Varey; Chris Goumas; Angela M Hong; Graham J Mann; Gerald B Fogarty; Jonathan R Stretch; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Kenneth J Lee; Michael J Quinn; John F Thompson; Richard A Scolyer
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

4.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

5.  Identification of FLOT2 as a novel target for microRNA-34a in melanoma.

Authors:  Rui Liu; Huiqing Xie; Chengqun Luo; Zizi Chen; Xiao Zhou; Kun Xia; Xiang Chen; Ming Zhou; Peiguo Cao; Ke Cao; Jianda Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-18       Impact factor: 4.553

6.  Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival.

Authors:  Faruk Tas; Kayhan Erturk
Journal:  Mol Clin Oncol       Date:  2017-10-04

7.  Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.

Authors:  Marta Polkowska; Paweł Ekk-Cierniakowski; Edyta Czepielewska; Wojciech Wysoczański; Wojciech Matusewicz; Małgorzata Kozłowska-Wojciechowska
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-12       Impact factor: 4.553

8.  sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.

Authors:  Mitchell E Fane; Brett L Ecker; Amanpreet Kaur; Gloria E Marino; Gretchen M Alicea; Stephen M Douglass; Yash Chhabra; Marie R Webster; Andrea Marshall; Richard Colling; Olivia Espinosa; Nicholas Coupe; Neera Maroo; Leticia Campo; Mark R Middleton; Pippa Corrie; Xiaowei Xu; Giorgos C Karakousis; Ashani T Weeraratna
Journal:  Clin Cancer Res       Date:  2020-11-01       Impact factor: 12.531

Review 9.  Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Authors:  Aljosja Rogiers; Joost J van den Oord; Marjan Garmyn; Marguerite Stas; Cindy Kenis; Hans Wildiers; Jean-Christophe Marine; Pascal Wolter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

10.  Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

Authors:  Charles M Balch; John F Thompson; Jeffrey E Gershenwald; Seng-Jaw Soong; Shouluan Ding; Kelly M McMasters; Daniel G Coit; Alexander M M Eggermont; Phyllis A Gimotty; Timothy M Johnson; John M Kirkwood; Stanley P Leong; Merrick I Ross; David R Byrd; Alistair J Cochran; Martin C Mihm; Donald L Morton; Michael B Atkins; Keith T Flaherty; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2014-02-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.